Bio-Rad Laboratories, Inc. (NYSE:BIO) has seen a
reduction in short interest by 10.6%, however, shareholders have experienced
losses of 14% this week, adding to a
53% loss over three years. Despite maintaining its revenue forecast for 2024,
shares have slipped. Large shareholders have been moving out, with
Swiss National Bank,
PEAK6 Investments LLC and others selling their shares. However, the company's financial status remains healthy with Q2 financial results overcoming expectations, despite recording a
greater loss per share compared to Q2 2023. The balance sheet remains stable, although BioPharma demand is decreasing, resulting in competitive pressure. Investors who stayed with Bio-Rad in the past three years have unfortunately
lost over half of their investment. The company's market value has been questioned, with its shares deemed to be running up too soon or too late. Despite these hiccups, some new investments have been noted and price targets have been raised. However, due to extended reports of revenue loss,
stocks are being downgraded.
Bio-Rad Laboratories Stocks News Analytics from Wed, 27 Jun 2018 01:17:35 GMT to Sun, 18 Aug 2024 15:36:10 GMT -
Rating -6
- Innovation -4
- Information 6
- Rumor -8
